(Q33908121)

29 July 2017

1 reference

title

Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis (English)

1 reference

29 July 2017

J Pope

1

1 reference

29 July 2017

D Fenlon

2

1 reference

29 July 2017

A Thompson

3

1 reference

29 July 2017

B Shea

4

1 reference

29 July 2017

D Furst

5

1 reference

29 July 2017

G Wells

6

1 reference

29 July 2017

A Silman

7

1 reference

29 July 2017

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

29 July 2017

1 reference

29 July 2017

CD000953

1 reference

29 July 2017

2

1 reference

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study

29 July 2017

1 reference

Crossref

https://api.crossref.org/works/10.1002%2F14651858.CD000953

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2F14651858.CD000953

Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis

21 January 2018

1 reference

12 December 2020

A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis

1 reference

12 December 2020

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

12 December 2020

A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases

1 reference

12 December 2020

Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis

1 reference

12 December 2020

Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study.

1 reference

12 December 2020

Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue

1 reference

12 December 2020

Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon.

1 reference

12 December 2020

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

1 reference

12 December 2020

Plasma exchange: a controlled study of the effect in patients with Raynaud's phenomenon and scleroderma

1 reference

12 December 2020

Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes.

1 reference

12 December 2020

A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome

1 reference

12 December 2020

The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis--a preliminary study

1 reference

12 December 2020

Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis

1 reference

12 December 2020

INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROME

1 reference

12 December 2020

Treatment of systemic sclerosis

1 reference

12 December 2020

Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon

1 reference

12 December 2020

10.1002/14651858.CD000953

Identifiers

DOI

1 reference

29 July 2017

1 reference